Press

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine

Jun 7 • 3 min read

Quick Take: Mindset Pharma’s MSP-1014, a differentiated psychedelic compound, showed greater safety and efficacy in in vitro and in vivo preclinical models Mindset Pharma Inc. (CSE: MSET), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it…

Pharmadrug’s Supersmart Launches Psilocybin Online Retail Platform in the Netherlands

Jun 7 • 4 min read

Quick Take: PharmaDrug has launched an online retail platform in The Netherlands and Europe. The online store will sell psilocybin truffles and functional mushrooms. PharmaDrug Inc. (CSE: BUZZ) a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to…

COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers

Jun 4 • 4 min read

Quick Take: COMPASS Pathways has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists. COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based…

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

Jun 3 • 3 min read

Quick Take MINDCURE has announced that it has completed the first stage of manufacturing pharmaceutical grade ibogaine. This ibogaine will be used in clinical research. Mind Cure Health Inc. (CSE: MCUR), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that it has completed the first stage of manufacturing pharmaceutical…

Appointment of MAC Clinical Research to accelerate timeline of Phase I/IIa clinical trial of SPL026 for Major Depressive Disorder

Jun 2 • 4 min read

Quick Take Small Pharma Inc. has announced the expansion of its Phase I/IIa clinical trial for its DMT based treatment. This expansion comes with the appointment of MAC Clinical Research to assist in the development of the trial. Small Pharma Inc. (TSXV: DMT), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announces the expansion of…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421